Jamie Heimburg-Molinaro

Jamie Heimburg-Molinaro

Auto-generated profile, based on publicly available information

Jamie Heimburg-Molinaro

Department of Surgery Beth Israel Deaconess Medical Center, Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2022 in Science Advances
Verified
Journal Article
Open access
YMYasuyuki Matsumoto
Yasuyuki Matsumoto
RARajindra Aryal
Rajindra Aryal
JHJamie Heimburg-Molinaro
Jamie Heimburg-Molinaro
Simon ParkSimon Park
Simon Park
WWWalter J. Wever
Walter J. Wever
Richard D. CummingsRichard D. Cummings
Richard D. Cummings
The underlying pathology of immunoglobulin A (IgA) nephropathy (IgAN), the most common glomerulonephritis worldwide, is driven by the deposition of immune complexes containing galactose-deficient IgA1 [Tn(+)IgA1] in the glomerular mesangium. Here, we report that novel anti-Tn circulating immune complexes (anti-Tn CICs) contain predominantly IgM, representing large macromolecular complexes of ~1.2 megadaltons to several megadalton sizes together with Tn(+)IgA1 and some IgG. These complexes are significantly elevated in sera of patients with IgAN, which contains higher levels of complement C3, compared to healthy individuals. Anti-Tn CICs are bioactive and induce specific proliferation of human renal mesangial cells. We found that these anti-Tn CICs can be dissociated with small glycomimetic compounds, which mimic the Tn antigen of Tn(+)IgA1, releasing IgA1 from anti-Tn CICs. This glycomimetic compound can also significantly inhibit the proliferative activity of anti-Tn CICs of patients with IgAN. These findings could enhance both the diagnosis of IgAN and its treatment, as specific drug treatments are now unavailable.

11 June 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
CGChao Gao
Chao Gao
KSKathrin Stavenhagen
Kathrin Stavenhagen
BEBarbara Eckmair
Barbara Eckmair
TMTanya R. McKitrick
Tanya R. McKitrick
AMAkul Mehta
Akul Mehta
Richard D. CummingsRichard D. Cummings
Richard D. Cummings
The recognition of oligomannose-type glycans in innate and adaptive immunity is elusive due to multiple closely related isomeric glycan structures. To explore the functions of oligomannoses, we developed a multifaceted approach combining mass spectrometry assignments of oligomannose substructures and the development of a comprehensive oligomannose microarray. This defined microarray encompasses both linear and branched glycans, varying in linkages, branching patterns, and phosphorylation status. With this resource, we identified unique recognition of oligomannose motifs by innate immune receptors, including DC-SIGN, L-SIGN, Dectin-2, and Langerin, broadly neutralizing antibodies against HIV gp120, N-acetylglucosamine-1-phosphotransferase, and the bacterial adhesin FimH. The results demonstrate that each protein exhibits a unique specificity to oligomannose motifs and suggest the potential to rationally design inhibitors to selectively block these protein-glycan interactions.

15 August 2013 in Journal of Virology
Verified
Journal Article
Open access
PDF file
XLXishan Lu
Xishan Lu
JQJianxun Qi
Jianxun Qi
Yi ShiYi Shi
Yi Shi
MWMing Wang
Ming Wang
DSDavid F. Smith
David F. Smith
GGGeorge F. Fu Gao
George F. Fu Gao
Interspecies transmission (host switching/jumping) of influenza viruses is a key scientific question that must be addressed. In addition to the vigorous research on highly pathogenic avian influenza viruses (HPAIVs), studies of the mechanism of interspecies transmission of low-pathogenic avian influenza viruses (LPAIVs) could also provide insights into host tropism and virulence evolution. Influenza A viruses harboring hemagglutinin (HA) H13 (e.g., H13N6) are LPAIVs. In this study, soluble H13 HA glycoprotein was purified, and its receptor binding activity was characterized. The results revealed that H13 exclusively binds the avian α2-3-linked sialic acid receptor; no binding to the mammalian α2-6-linked sialic acid receptor was detected. Furthermore, the molecular basis of the H13 receptor binding specificity was revealed by comparative analysis of the crystal structures of both receptor-bound H13 and H5 HAs, which might be contributed by the hydrophobic residue V186. Work with an H13N186 mutant confirmed the importance of V186 in the receptor binding specificity of H13 HA, which shows that the mutant protein reduced the binding of an avian receptor analog but increased the binding of a human receptor analog. Detailed structural analysis also demonstrated that the conserved binding sites of the recently well-studied broadly neutralizing human monoclonal antibodies targeting the HA2 domain are found in H13. Our results expand our understanding of virulence evolution, receptor binding preference, and species tropism of the LPAIVs and HPAIVs.

21 September 2024 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
JHJamie Heimburg-Molinaro
Jamie Heimburg-Molinaro
AMAkul Mehta
Akul Mehta
CTCatherine A. Tilton
Catherine A. Tilton
Richard D. CummingsRichard D. Cummings
Richard D. Cummings
Glycans linked to proteins and lipids and also occurring in free forms have many functions, and these are partly elicited through specific interactions with glycan-binding proteins (GBPs). These include lectins, adhesins, toxins, hemagglutinins, growth factors, and enzymes, but antibodies can also bind glycans. While humans and other animals generate a vast repertoire of GBPs and different glycans in their glycomes, other organisms, including phage, microbes, protozoans, fungi, and plants also express glycans and GBPs, and these can also interact with their host glycans. This can be termed the protein-glycan interactome, and in nature is likely to be vast, but is so far very poorly described. Understanding the breadth of the protein-glycan interactome is also a key to unlocking our understanding of infectious diseases involving glycans, and immunology associated with antibodies binding to glycans. A key technological advance in this area has been the development of glycan microarrays. This is a display technology in which minute quantities of glycans are attached to the surfaces of slides or beads. This allows the arrayed glycans to be interrogated by GBPs and antibodies in a relatively high throughput approach, in which a protein may bind to one or more distinct glycans. Such binding can lead to novel insights and hypotheses regarding both the function of the GBP, the specificity of an antibody and the function of the glycan within the context of the protein-glycan interactome. This article focuses on the types of glycan microarray technologies currently available to study animal glycobiology and examples of breakthroughs aided by these technologies.

5 June 2021 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
KSKathrin Stavenhagen
Kathrin Stavenhagen
LLLisa C. Laan
Lisa C. Laan
CGChao Gao
Chao Gao
AMAkul Mehta
Akul Mehta
JHJamie Heimburg-Molinaro
Jamie Heimburg-Molinaro
Richard D. CummingsRichard D. Cummings
Richard D. Cummings

13 October 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KSKathrin Stavenhagen
Kathrin Stavenhagen
AMAkul Mehta
Akul Mehta
LLLisa Laan
Lisa Laan
CGChao Gao
Chao Gao
JHJamie Heimburg-Molinaro
Jamie Heimburg-Molinaro
Richard D. CummingsRichard D. Cummings
Richard D. Cummings
The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis. Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner. Previous studies indicated that self-glycosylation of MR regulates its glycan binding. To further explore this structure-function relationship, we studied herein a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc). The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties. We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes. Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs. Regalactosylation of N-glycans rescues mannose binding by MR-Fc. Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.